scholarly journals Dynamic Thiol/Disulphide Homeostasis in Children and Adolescents with Non-Autoimmune Subclinical Hypothyroidism

2018 ◽  
Vol 27 (1) ◽  
pp. 44-48 ◽  
Author(s):  
Seyit Ahmet Uçaktürk ◽  
Murat Alışık ◽  
Çağatay Uğur ◽  
Selin Elmaoğulları ◽  
Eda Mengen ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Subclinical Hypothyroidism ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Peroxidase ◽  
Control Subjects ◽  
The Status ◽  
Healthy Control ◽  
And Control

Objective: To evaluate the thiol/disulphide homeostasis in children with non-autoimmune subclinical hypothyroidism (SHT). Subjects and Methods: Thiol/disulphide homeosta sis, involving native thiol (SH), disulphide (SS), and total thiol (SS + SH), was evaluated in 60 children and adolescents who were negative for thyroid auto-antibodies (anti-thyroid peroxidase, anti-thyroglobulin) and had a thyroid-stimulating hormone (TSH) value of > 5 mIU/L, and in 40 sex- and age-matched healthy control subjects who were negative for thyroid autoantibodies and had normal TSH levels. Lipid profiles and urine iodine levels were also determined. Results: SH (466 ± 32.8 vs. 462 ± 32.1 μmol/L p = 0.59), SH + SS (508 ± 34.0 vs. 506 ± 32.7 μmol/L, p = 0.81), SS (21 ± 5.5 vs. 22 ± 5.8 μmol/L, p = 0.41), SS/SH (4.5 ± 1.2 vs. 4.8 ± 1.3%, p = 0.36), SS/SH + SS (4.1 ± 1.0 vs. 4.3 ± 1.1%, p = 0.36) and SH/SH + SS (91 ± 2.1 vs. 91 ± 2.1%, p = 0.31) levels were similar in children with SHT and control subjects (p > 0.05). There was no difference between total cholesterol, triglyceride, and low-density lipoprotein levels in SHT patients and controls. No difference was detected between the patients with or without iodine deficiency in the SHT group in terms of thiol/disulphide homeostasis parameters. Conclusion: The status of dynamic thiol/disulphide homeostasis did not change in children and adolescents with non-autoimmune SHT. Future studies are needed for the evaluation of oxidative stress in patients with long-standing non-autoimmune SHT.

scholarly journals Comparison of ox-LDL Levels in Diabetic Patients with Normo-, Micro-, and Macroalbuminuria with Their First Degree Relatives and the Healthy Control Group

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Parisa Behzadi ◽  
Firouzeh Torabi ◽  
Massoud Amini ◽  
Ashraf Aminorroaya
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cross Sectional Study ◽  
Control Group ◽  
Diabetic Patients ◽  
Cross Sectional ◽  
First Degree Relatives ◽  
Significant Difference ◽  
Healthy Control ◽  
And Control

Oxidized low density lipoprotein (ox-LDL) is a product of oxidative stress. In this cross-sectional study, we compared the ox-LDL concentrations in diabetic patients with normoalbuminuria (n=28), microalbuminuria (n=28), and macroalbuminuria (n=28) with their first degree relatives (n=28) and healthy control people (n=31). They were selected by consecutive patient selection method. The ox-LDL level was assayed using ELISA. We measured blood pressure, lipid profile, fasting plasma glucose (FPG), and HbA1c in all groups. There was no significant difference in ox-LDL concentrations among normoalbuminuric, microalbuminuric, and macroalbuminuric diabetic groups. In diabetic patients with micro- and macroalbuminuria, ox-LDL concentration was higher than their first degree relatives (P=0.04andP=0.03) and control group (P=0.001andP=0.03, resp.). In normoalbuminuric diabetic persons, ox-LDL concentration was just higher than that of healthy people (P=0.02). There was no statistically significant difference in ox-LDL levels between normoalbuminuric diabetic patients and their first degree relatives. In conclusion, the presence and progression of albuminuria in diabetic patients are not related to ox-LDL concentration and genetic predisposition influences the plasma OX-LDL level. Larger sample size is needed to confirm this conclusion in future studies.

Thyroid evaluation of children and adolescents with Williams syndrome in Zhejiang Province

2017 ◽  
Vol 30 (12) ◽  
Author(s):  
Wei-Jun Chen ◽  
Chai Ji ◽  
Dan Yao ◽  
Zheng-Yan Zhao
Keyword(s):  
Children And Adolescents ◽  
Thyroid Function ◽  
Williams Syndrome ◽  
Subclinical Hypothyroidism ◽  
Thyroid Stimulating Hormone ◽  
Zhejiang Province ◽  
Overt Hypothyroidism ◽  
Thyroid Peroxidase ◽  
Thyroid Antibodies ◽  
Free Triiodothyronine

AbstractBackground:The objective of the study was to describe the prevalence of abnormal thyroid function and volume in children and adolescents with Williams syndrome (WS) in Zhejiang Province, China.Methods:Thyroid function, including thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), and thyroid antibodies (thyroid peroxidase and thyroglobulin) were measured in 83 patients with WS, aged 0.2–16.5 years. Twenty-three patients were followed for an average of 1.7 years (0.4–4.1), and multiple TSH determinations were considered. Thyroid ultrasonography was performed on 49 patients.Results:One patient was diagnosed with overt hypothyroidism, and 23 patients (27%) had subclinical hypothyroidism (SH). Thyroid antibodies were absent in all patients. In five age groups (0–1 years, 1–3 years, 3–6 years, 6–9 years, 9–18 years), the prevalence of patients with subclinical hypothyroidism was 25%, 28.5%, 44.4%, 16.7% and 4.7%, respectively. Through ultrasound examination, 21 patients (42%) were observed to have thyroid hypoplasia (TH), and there were no cases of thyroid haemiagenesis. The incidence rate of TH increased with age, rising from 20% in the youngest group to 66% in the oldest.Conclusions:SH and TH is common in children and adolescents with WS. Yearly evaluation of thyroid must be performed in all patients in this population, regardless of the result of the neonatal screening. Age under 6 years and existing thyroid abnormalities are risk factors for developing SH, and a shorter follow-up interval is needed for screening in these individuals, SH is often self-limiting, and clinicians should be alert to overt hypothyroidism.

scholarly journals Circulating Betatrophin Is Increased in Patients with Overt and Subclinical Hypothyroidism

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Cheng Han ◽  
Xinghai Xia ◽  
Aihua Liu ◽  
Xiaowen Zhang ◽  
Mi Zhou ◽  
...  
Keyword(s):  
Subclinical Hypothyroidism ◽  
Thyroid Dysfunction ◽  
Metabolic Diseases ◽  
Thyroid Autoimmunity ◽  
Thyroid Stimulating Hormone ◽  
Overt Hypothyroidism ◽  
Thyroid Peroxidase ◽  
Thyroid Peroxidase Antibody ◽  
Antibody Positivity ◽  
Healthy Control

Thyroid hormone (TH) affects many metabolic processes such as promoting oxidation of sugar, fat, and protein in many tissues. Thyroid dysfunction is associated with metabolic disorders. The newly discovered adipocyte- and hepatocyte-derived cytokine, betatrophin, has been reported to be involved in metabolic diseases, but its influence on thyroid dysfunction is uncertain. Therefore, the present study aims to evaluate circulating betatrophin levels in subjects with different thyroid function status and to predict the factors associated with betatrophin levels, especially whether thyroid stimulating hormone (TSH), TH, or thyroid autoantibodies are associated with betatrophin levels. In the study, serum betatrophin was measured in the subjects grouped as overt hypothyroidism (OH), subclinical hypothyroidism (SCH), euthyroid with isolated thyroid peroxidase antibody positivity (isolated Ab), and healthy control (HC), according to their thyroid functions. From our results, we found that betatrophin may be associated with thyroid insufficiency but not thyroid autoimmunity. Thus, when interpreting the results of betatrophin, thyroid functions should also be taken into consideration.

scholarly journals Association of serum irisin concentration with thyroid autoantibody positivity and subclinical hypothyroidism

2021 ◽  
Vol 49 (5) ◽  
pp. 030006052110184
Author(s):  
Zhengyi Chen ◽  
Qiao Zhang ◽  
Nianchun Peng ◽  
Ying Hu ◽  
Hong Li ◽  
...  
Keyword(s):  
Subclinical Hypothyroidism ◽  
Density Lipoprotein ◽  
Cross Sectional Study ◽  
Thyroid Stimulating Hormone ◽  
Control Group ◽  
Thyroid Peroxidase ◽  
Serum Samples ◽  
Cross Sectional ◽  
Thyroid Autoantibody ◽  
Glucose Levels

Objective This study evaluated the association of serum irisin level with thyroid autoantibody (TAA) positivity and subclinical hypothyroidism (SH). Methods In this cross-sectional study, 334 participants were assigned to one of the following four age- and sex-matched groups: TAA plus SH (84 patients), isolated TAA (83 patients), isolated SH (83 patients), or healthy controls (84 individuals). Irisin and creatine kinase (CK) were measured in serum samples. Results Patients with TAA plus SH, isolated TAA, and isolated SH had higher irisin levels compared with the controls. There was a significant increase in the irisin level in the TAA plus SH group compared with the control group. Among all participants, the irisin levels were positively associated with thyroglobulin and thyroid peroxidase antibody titers and high-density lipoprotein cholesterol levels, but negatively associated with waist circumference, glycated hemoglobin levels, and fasting plasma glucose levels. The irisin level was not associated with the thyroid-stimulating hormone, free thyroxine, or CK levels. Irisin levels were independently associated with TAA, with or without SH, but they were not associated with SH alone. Conclusions Irisin level may help to predict the risk of developing TAA with or without SH.

scholarly journals New insights into the pathological development of dyslipidemia in patients with hypothyroidism

2021 ◽  
Author(s):  
Xin Su ◽  
Xiang Chen ◽  
Hua Peng ◽  
Jingjin Song ◽  
Bin Wang ◽  
...  
Keyword(s):  
Thyroid Hormones ◽  
Metabolic Diseases ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Underlying Mechanism ◽  
Thyroid Stimulating Hormone ◽  
Transformation Process ◽  
Serum Concentrations ◽  
The Status ◽  
Pathological Development

According to the previous reports, hypothyroidism has been shown to be strongly correlated with increased circulating concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG). Notably, thyroid hormones  are confirmed to modulate the production, clearance, and transformation process of cholesterol within circulation of mammals. Moreover, emerging evidence suggests that the thyroid-stimulating hormone could also participate in modulating serum lipid metabolism independently of thyroid hormones, which further induces the pathological development of dyslipidemia. However, the underlying mechanism is still not fully elucidated. Recently, several research studies have demonstrated that the pathogenic progression of hypothyroidism-related dyslipidemia might be correlated with the decreased serum concentrations of thyroid hormones and the increased serum concentrations of thyroid-stimulating hormones. Thus, this indicates that hypothyroidism could induce dyslipidemia and its related cardio-metabolic disorder diseases. In addition, several newly identified modulatory biomarkers, such as proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-like protein (ANGPTLs), and fibroblast growth factors (FGFs), might play an important role in the regulation of dyslipidemia induced by hypothyroidism. Furthermore, under the status of hypothyroidism, significantly dysfunctional HDL particles could also be observed. In the current review, we summarized the recent knowledge of the relationship between the development of hypothyroidism with dyslipidemia. We also discussed the updated understanding of the mechanisms whereby hypothyroidism induces the risk and the development of dyslipidemia and cardio-metabolic diseases. 

scholarly journals Adipokine expression and endothelial function in subclinical hypothyroidism rats

2018 ◽  
Vol 7 (2) ◽  
pp. 295-304 ◽  
Author(s):  
Ningning Gong ◽  
Cuixia Gao ◽  
Xuedi Chen ◽  
Yu Wang ◽  
Limin Tian
Keyword(s):  
Adipose Tissue ◽  
Endothelial Function ◽  
Subclinical Hypothyroidism ◽  
Pearson Correlation ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Thyroid Stimulating Hormone ◽  
Control Group ◽  
Tnf Α ◽  
Male Wistar Rats

The purpose of our study was to observe adipokine expression and endothelial function in subclinical hypothyroidism (sHT) rats and to determine whether levothyroxine (LT4) treatment affects these changes. Sixty-five male Wistar rats were randomly divided into five groups: the control group; sHT A, B and C groups and the sHT + T4 group. The sHT rats were induced by methimazole (MMI) and the sHT + T4 rats were administered LT4 treatment after 8 weeks of MMI administration. Thyroid function and lipid levels were measured using radioimmunoassays and enzymatic colorimetric methods, respectively. Serum adiponectin (APN), chemerin, TNF-α, endothelin (ET-1) and nitric oxide (NO) levels were measured using ELISA kits and a nitric-reductive assay. The expression of APN, chemerin and TNF-α in visceral adipose tissue (VAT) was measured in experimental rats using RT-PCR and Western blotting. Hematoxylin–eosin (HE) staining was used to observe changes in adipose tissue. The sHT rats had significantly higher levels of thyroid-stimulating hormone (TSH), TNF-α, chemerin, ET-1, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) and lower levels of APN and NO than those in control and sHT + T4 rats. Based on Pearson correlation analysis, the levels of chemerin, TNF-α, ET-1, LDL-C, TC and triglyceride (TG) were positively correlated with TSH, but APN and NO levels were negatively correlated with TSH. These findings demonstrated that high TSH levels contribute to the changes of adipokines and endothelial dysfunction in sHT, but LT4 treatment ameliorates those changes.

Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy

1998 ◽  
Vol 95 (4) ◽  
pp. 489-495 ◽  
Author(s):  
J. JANKOWSKI ◽  
J.-R. NOFER ◽  
M. TEPEL ◽  
B. GRIEWEL ◽  
H. SCHLÜTER ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Human Serum ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Oxidized Low Density Lipoprotein ◽  
Simple Method ◽  
Control Subjects ◽  
Healthy Control

1.In this study we compared the 500 MHz 1H-NMRs from native and oxidized low-density lipoproteins. 2.The measurements revealed a characteristic pattern of three resonances in spectra from oxidized, but not from native low-density liprotein at 1.17 p.p.m., 1.18 p.p.m. and 1.20 p.p.m. (relative to 3-trimethylsilyl-[2,2,3,3-2H4]-propionate). 3.A quantitative comparison between these resonances in sera from patients with coronary heart disease and healthy control subjects revealed that the intensity was significantly higher in patients with coronary heart disease (1.17 p.p.m.: 0.026±0.014 versus 0.015±0.019; 1.18 p.p.m.: 0.032±0.011 versus 0.017±0.021; 1.20 p.p.m.: 0.030±0.066 versus 0.010±0.005; P< 0.05 compared with healthy control subjects for each resonance). 4.Fractionation of sera from patients with coronary heart disease revealed that the resonances equal to those obtained from experimentally oxidized low-density lipoprotein are indeed caused by the low-density lipoprotein fraction of the sera. 5.When the NMRs from sera were calibrated with oxidized low-density lipoprotein prepared by Cu2+ oxidation, a concentration of 66.5±28.6 ;μg/ml and 36.3±23.7 ;μg/ml (P< 0.05) was estimated in patients with coronary heart disease and healthy subjects respectively. Elevated levels of oxidized low-density lipoprotein also occurred in those patients with normal serum concentrations of total low-density lipoprotein. 6.The study shows a simple method to measure oxidized low-density lipoprotein in human serum and may gain interest to assess the cardiovascular risk factor profiles more completely.

Effects of Subclinical Hypothyroidism and Its Treatment on Serum Lipids

2003 ◽  
Vol 37 (5) ◽  
pp. 725-730 ◽  
Author(s):  
Beata A Ineck ◽  
Tien MH Ng
Keyword(s):  
Subclinical Hypothyroidism ◽  
Serum Lipids ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Thyroid Stimulating Hormone ◽  
Mesh Terms ◽  
Atherogenic Lipid Profile ◽  
Thyroxine Replacement ◽  
Thyroxine Replacement Therapy ◽  
Lipid Abnormalities

OBJECTIVE: To determine whether the literature supports an effect of subclinical hypothyroidism on serum lipids and, if so, what are the effects of thyroxine replacement therapy. DATA SOURCES: Articles were identified on MEDLINE using the MeSH terms hypothyroidism, lipids, or cholesterol. DATA SYNTHESIS: The majority of studies that determined the prevalence of lipid abnormalities in subclinical hypothyroidism and studies that evaluated the effects of thyroxine replacement on lipids were small, uncontrolled, and varied in inclusion criteria. Six randomized, placebo-controlled trials were identified that evaluated the effect of levothyroxine on lipids in subclinically hypothyroid patients. CONCLUSIONS: Subclinical hypothyroidism can potentially contribute to a pro-atherogenic lipid profile, with effects being greater at higher thyroid-stimulating hormone levels. Thyroxine replacement reduces total cholesterol and low-density lipoprotein cholesterol, with no effect on triglycerides. Effects on high-density lipoprotein, lipoprotein (a), and apolipoproteins A1 and B require further study. Larger prospective studies are needed to clarify many issues.

scholarly journals Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis

2012 ◽  
Vol 35 (3) ◽  
pp. 144 ◽  
Author(s):  
Abdolkarim Mahrooz ◽  
Mehryar Zargari ◽  
Omid Sedighi ◽  
Hamed Shaygani ◽  
Ghorban Gohari
Keyword(s):  
Oxidized Ldl ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Pon1 Activity ◽  
Control Group ◽  
Control Subjects ◽  
Increased Risk ◽  
The Status ◽  
Serum Paraoxonase ◽  
Esrd Patients

Purpose: Investigations, in which oxidized-low density lipoprotein (ox-LDL), serum paraoxonase (PON1) and homocysteine (Hcy) are considered together as important agents involved in the development of oxidative and atherogenic events in non-diabetic hemodialysis (HD) population, are limited. This case-control study was designed to evaluate these parameters in the patients and control subjects and to determine the correlations among the factors. Methods: Forty-nine age- and sex- matched subjects, including 28 non-diabetic HD patients (paired pre-and post-dialysis samples) and 21 control subjects, were enrolled. Ox-LDL and Hcy levels were measured with ELISA and EIA methods, respectively. Arylesterase activity of PON1 was measured by spectrophotometric assay. Results: Compared with the control group, ox-LDL levels were significantly increased both before (p=0.001) and after HD (p=0.036). Arylesterase activity-to-HDL ratio in HD patients was significantly higher than control subjects (p=0.003). Homocysteine levels in the ESRD patients were higher than control subjects both in pre-dialysis and post-dialysis. There was a significant positive correlation (r= 0.25, p= 0.026) between ox-LDL and homocysteine in samples obtained before HD. Logistic regression analysis revealed ox-LDL levels (OR=3.02, p < 0.001) and arylesterase activity/HDL ratio (OR=2.43, p=0.01) to be associated with the increased risk of ESRD. Conclusions: Ox-LDL levels and arylesterase activity/HDL ratio indicated the strongest association with ESRD risk. These factors, especially ox-LDL as an indicator of oxidative stress, may be biomarkers in evaluating the status of non-diabetic ESRD patients. Because of the pathogenic relationship between ox-LDL and homocysteine as nontraditional risk factors of atherosclerosis, therapeutic strategies adopted to reduce them may be useful in decrease of high prevalence of cardiovascular mortality in dialysis patients. In addition, measurement of PON1 activity to HDL ratio is possibly a more valuable biomarker than arylesterase activity alone in non-diabetic ESRD.

scholarly journals ASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM WITH METABOLIC SYNDROME: A CROSS-SECTIONAL STUDY

2020 ◽  
pp. 1-4
Author(s):  
Rajesh Kumar Jha ◽  
Sanjay Nath Jha ◽  
Vinayanand Jha ◽  
Krishna Kumar Jha ◽  
Debarshi Jana
Keyword(s):  
Metabolic Syndrome ◽  
Subclinical Hypothyroidism ◽  
Demographic Data ◽  
Low Density Lipoprotein ◽  
Strong Association ◽  
Density Lipoprotein ◽  
Cross Sectional Study ◽  
Thyroid Stimulating Hormone ◽  
Sectional Study ◽  
Cross Sectional

Objective: Metabolic syndrome (MetS) and subclinical hypothyroidism (SCH) both are known to have adverse cardiovascular outcomes. Available studies have shown variable results on the association of SCH with MetS as well as individual components of MetS. We aimed to study the association of SCH with MetS and its individual components of MetS. Material and Methods: This cross-sectional study was carried out in individuals volunteered for health checkup at Department of Medicine, Darbhanga Medical College and Hospital, Laheriasarai, Bihar. About 60 cases with MetS and 120 controls without having MetS were recruited. Demographic data such as history of diabetes mellitus, hypertension, dyslipidemia, blood pressure (BP), waist circumference and serum T3, serum T4, thyroid stimulating hormone, fasting blood sugar, fasting lipid profile, and hemoglobin A1c were collected and statistically analyzed. Statistical analysis was done by using SPSS sav software packages. Chi-square test was used for the comparison of qualitative data. Results: SCH was present in 52 (28.9%) among 180 study participants. SCH was present in 35 (58.33%) participants having MetS and in 17 (14.16%) of controls. There was a strong association between SCH and MetS (p<0.001). Significant association of SCH with diastolic BP (p=0.017) and with central obesity (p=0.004) was observed but not with high-density lipoprotein, triglyceride, hyperglycemia, systolic BP, total cholesterol, and low-density lipoprotein. Conclusion: We observed a strong association of SCH with MetS. We also observed significant association of SCH with diastolic BP and with obesity. The finding of this study indicates the need to screen individuals with MetS for SCH.

Sign in / Sign up

Export Citation Format

Share Document